
Oncology NEWS International
- Oncology NEWS International Vol 4 No 1
- Volume 4
- Issue 1
ASCO Names John Durant, MD, as Executive VP and Washington Lobbyist
WASHINGTON--John Durant, MD, has been named to the newly created position of executive vice president of the American Society of Clinical Oncology (ASCO). Formerly president of ASCO and a member of its board of directors, Dr. Durant will become the society's leading spokesman and advocate in Washington on April 1. He is currently vice president for health affairs and director of the medical school at the University of Alabama at Birmingham.
WASHINGTON--John Durant, MD, has been named to the newly createdposition of executive vice president of the American Society ofClinical Oncology (ASCO). Formerly president of ASCO and a memberof its board of directors, Dr. Durant will become the society'sleading spokesman and advocate in Washington on April 1. He iscurrently vice president for health affairs and director of themedical school at the University of Alabama at Birmingham.
Articles in this issue
over 31 years ago
MDs Fear Managed Care Equals Lower-Quality Careover 31 years ago
Dallas Medical Center Launches Umbilical Stem Cell Projectover 31 years ago
Ethyol Approved for Use in the UKover 31 years ago
Assessment Tools Are Essential to Improve Management of Painover 31 years ago
Undertreating Pain Costs Money in the Long Run, Physician Warnsover 31 years ago
After 5 Years as Head, Dr. Broder Plans to Resign His Post at NCIover 31 years ago
EORTC Endometrial Ca Trial Challenges Findings From GOGRelated Content


TIP113 HERTHENA-PanTumor01 (NCT06172478): Expansion of a Global Phase 2 Trial of HER3-DXd in Patients With Advanced/Metastatic HR+/HER2− Breast Cancer




















































